Fresenius Delivers First US Biosimilar Approval

Kabi Receives Long-Awaited Nod From FDA For Stimufend Version Of Pegfilgrastim

 
• By Dave Wallace

Fresenius Kabi has set out launch plans after receiving its first US biosimilar approval, for its Stimufend pegfilgrastim rival to Neulasta.

US flag thumbs up
Fresenius Kabi has its first US biosimilar approval • Source: Shutterstock

More from Biosimilars

More from Products